Sandy Feng, Ming Si, Sarah E. Taranto, Maureen A. McBride, Christine Mudge, Susan Stritzel, John P. Roberts, Philip Rosenthal – 22 March 2006 – During the last 10 to 15 years, medical and surgical innovations have established pediatric liver transplantation as the optimal therapy for children suffering acute and chronic liver disease. We hypothesized that the profile of current pediatric liver transplant recipients would differ significantly from that of an earlier era.

Silvia Riva, Aurelio Sonzogni, Michela Bravi, Alessandro Bertani, Maria Grazia Alessio, Manila Candusso, Paola Stroppa, Maria L. Melzi, Marco Spada, Bruno Gridelli, Michele Colledan, Giuliano Torre – 22 March 2006 – Late graft dysfunction (GD) associated with the development of autoantibodies is a common event after pediatric liver transplantation (OLTx) and can present in 2 clinicohistological subsets: de novo autoimmune hepatitis (DNAH) and early chronic rejection (ECR). Sixty out of 247 children developed autoantibodies after OLTx.

Xiao Xu, Kwan Man, Shu Sen Zheng, Ting Bo Liang, Terence K. Lee, Kevin T. Ng, Sheung Tat Fan, Chung Mau Lo – 22 March 2006 – The major concern of living donor liver transplantation is small‐for‐size graft injury at the early phase after transplantation. Novel therapeutic strategies should be developed. To investigate the protective effect of somatostatin related to hemodynamic stress on small‐for‐size liver graft injury, we applied a treatment regimen of low‐dose somatostatin in a rat orthotopic liver transplantation model using small‐for‐size grafts (median, 38.7%; range, 35–42%).

Victor W. Xia, Bin Du, Michelle Braunfeld, Gundappa Neelakanta, Ke‐Qin Hu, Hamid Nourmand, Philip Levin, Ronald Enriquez, Jonathan R. Hiatt, R. Mark Ghobrial, Douglas G. Farmer, Ronald W. Busuttil, Randolph H. Steadman – 22 March 2006 – Recent changes in organ allocation based on the model for end‐stage liver disease (MELD) prioritize the most ill patients on the waiting list for liver transplantation. While patients undergoing liver transplantation in the MELD era are more acutely ill, the impact of the policy changes on perioperative management has not been completely assessed.

Jürg Reichen – 22 March 2006

Federico N. Aucejo, Werner Andrade Ortiz, Dympna Kelly, Charles Winans, David Vogt, Bijan Eghtesad, John J. Fung, Charles M. Miller – 22 March 2006

Shaun P. Cordoba, Chuanmin Wang, Rohan Williams, Jian Li, Lynn Smit, Alexandra Sharland, Richard Allen, Geoffrey McCaughan, Alex Bishop – 22 March 2006 – This study aimed to define the molecular mechanism during induction of spontaneous liver transplant tolerance using microarrays and to focus on molecular pathways associated with tolerance by meta‐analysis with published studies. The differences in the early immune response between PVG to DA liver transplant recipients that are spontaneously tolerant (TOL) and PVG to Lewis liver transplants that reject (REJ) were examined.

Tomohide Hori, Taku Iida, Shintaro Yagi, Kentaro Taniguchi, Chiduru Yamamoto, Shugo Mizuno, Kentaro Yamagiwa, Shuji Isaji, Shinji Uemoto – 22 March 2006 – Reliable monitoring enabling evaluation of graft function is crucial after living‐donor liver transplantation (LDLT). A method to identify poor graft function at an early postoperative period would allow opportune intensive clinical management to bring about further improvements in LDLT outcomes.

Francesco Menichetti, Maria Lucia Bindi, Carlo Tascini, Lucio Urbani, Gianni Biancofiore, Roberta Doria, Massimo Esposito, Roberto Mozzo, Gabriele Catalano, Franco Filipponi – 22 March 2006 – A case of post‐transplant malaria is described. The patient presented fever and severe anemia after orthotopic liver transplantation. Diagnosis was made only after the review of donor characteristics. Although a high parasitemia was found at the moment of diagnosis, the treatment with quinine and doxycycline was successful.

Paul Angulo – 22 March 2006 – Nonalcoholic fatty liver disease affects a substantial proportion of the general population worldwide. This high prevalence of nonalcoholic fatty liver disease has important consequences in the donor selection process for liver transplantation, and in the posttransplant period given the high recurrence rate of disease. This paper reviews the prevalence of nonalcoholic fatty liver disease, its progressive potential, and the implications of this liver condition in both the pre‐ and post‐liver transplantation setting. Liver Transpl 12:523–534, 2006.